文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

澳大利亚转移性结直肠癌一线化疗中5-氟尿嘧啶个体化与标准给药的药物经济学评价

Economic evaluation of personalized vs. standard dosing of 5-fluorouracil in first-line chemotherapy for metastatic colorectal cancer in Australia.
PubMed 文献 · Br J Clin Pharmacol · 2024-02-12

本研究从澳大利亚医疗系统视角,构建半马尔可夫模型比较PK指导与BSA指导的5-FU给药(FOLFOX方案)用于mCRC患者的经济性。PK组获得1.751 QALYs、花费32 564澳元,BSA组获得1.291 QALYs、花费36 379澳元,PK指导给药为优势策略。敏感性分析显示ICER始终低于每QALY 50 000澳元,但模型基于有限低质量证据。

要点

  • PK指导的5-FU给药较BSA给药可改善生存并降低毒性,在澳大利亚具成本节约优势。
  • PK组QALYs更高(1.751 vs 1.291)且总成本更低(32 564 vs 36 379澳元)。
  • ICER在所有敏感性分析中均低于每QALY 50 000澳元阈值。

核心结论

  • 在澳大利亚医疗系统视角下,mCRC患者使用PK指导的5-FU给药(FOLFOX方案)相比BSA指导给药为优势策略,兼具更优健康产出与更低成本。

研究设计与样本

  • 研究构建含四个健康状态的半马尔可夫模型,从澳大利亚医疗系统视角比较PK指导与BSA指导的5-FU给药(FOLFOX方案)用于mCRC患者。
  • 转移概率来自拟合的生存模型,效用值取自已发表研究,并进行了单因素和概率敏感性分析。

主要发现

  • BSA指导的FOLFOX获得1.291 QALYs,成本为36 379澳元;PK指导的FOLFOX获得1.751 QALYs,成本为32 564澳元。
  • 对总体ICER影响最大的变量为BSA组和PK组的不良事件发生率、模型时间跨度、无进展生存效用值及PREDICT检测成本。
  • 单因素和多因素敏感性分析显示,PK FOLFOX的ICER在所有测试变量下均持续低于每QALY 50 000澳元。

关键数值与推荐

  • PK指导FOLFOX:1.751 QALYs,成本32 564澳元;BSA指导FOLFOX:1.291 QALYs,成本36 379澳元。
  • ICER在所有敏感性分析中均低于每QALY 50 000澳元。

临床怎么用

  • 对于mCRC一线FOLFOX化疗患者,采用PK指导的5-FU剂量管理在澳大利亚背景下可能节约成本并改善健康产出。
  • 模型估计基于有限低质量证据,临床决策应结合后续随机对照试验结果综合判断。

局限性

  • 模型估计基于有限、低质量的证据。
  • 需要直接比较PK指导与BSA指导给药在当前多种方案中的随机对照试验证据来解决模型不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Using pharmacokinetics (PK)-guided 5-fluorouracil (5-FU) for metastatic colorectal cancer (mCRC) improves overall survival (OS) and decreases toxicity, yet its value for money in the Australian setting is unknown. Our study assesses the cost-effectiveness of PK vs. body surface area (BSA) dosing of 5-FU for patients with mCRC. METHODS: We developed a semi-Markov model with four health states to compare PK-guided dosing within a FOLFOX regimen vs. BSA-guided dosing for mCRC patients from an Australian healthcare system perspective. Transition probabilities were derived from fitted survival models, with utility values obtained directly from published studies. We calculated direct healthcare costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs), and included both one-way and probabilistic sensitivity analyses. RESULTS: BSA-guided FOLFOX provided 1.291 QALYs at a cost of $36 379, compared with PK-guided FOLFOX which delivered 1.751 QALYs at a cost of $32 564. Therefore, PK-guided dosing emerges as the dominant strategy offering both better health outcomes and lower costs. The variables that had the greatest impact on the overall ICER were the adverse event rates in the BSA and PK groups, model time horizon, utility of progression-free survival and PREDICT assay cost. Our univariate and multivariate sensitivity analysis confirmed that the ICER for PK FOLFOX consistently remained below $50 000 per QALY across all tested variables. CONCLUSIONS: PK dose management of 5-FU-based chemotherapy in mCRC patients appears to be a cost-saving strategy in Australia. However, our model estimates are drawn from limited, low-quality evidence. Further evidence from randomized controlled trials (RCTs), directly comparing PK-based to BSA-based dosing across a variety of current regimens, is needed to address our model's uncertainties.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Erku D, Martin JH, Michael M, et al. Economic evaluation of personalized vs. standard dosing of 5-fluorouracil in first-line chemotherapy for metastatic colorectal cancer in Australia. Br J Clin Pharmacol. 2024. PMID: 38346317. doi:10.1111/bcp.16013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。